Heart Rhythm Society (HRS)

The Heart Rhythm Society (HRS) is the primary U.S. medical society for electrophysiology (EP). The organization promotes education and advocacy for cardiac arrhythmia professionals and patients, including setting policy guidelines and offering expert consensus.

The EBR Systems WiSE leadless cardiac resynchronization therapy (CRT) system. #HRS23

A leadless pacemaker the size of a grain of rice delivers cardiac resynchronization therapy

Results from a pivotal clinical trial presented as a late-breaker at Heart Rhythm 2023 indicate that a new leadless pacemaker technology can deliver cardiac resynchronization therapy in patients who were not able to be treated with conventional CRT and epicardial leads.

Left bundle branch pacing emerges as an alternative to biventricular pacing in two late-breaking trials

The use of left bundle branch area pacing (LBBAP) is growing in electrophysiology implanted devices. Two late-breaking studies at Heart Rhythm 2023 highlight the success of LBBAP as an alternative to the standard of care using biventricular pacing.

Thumbnail

Links to all the late-breaking trials for Heart Rhythm 2023

Heart Rhythm 2023, the society's 44th annual meeting, is scheduled for May 19-21. 

Images from the consensus document showing the proper left atrial appendage (LAA) sizing assessment for a transcatheter occluder device using transesophageal echo (TEE). Sizing and evaluation for pre-existing thrombus in the LAA also can be performed using cardiac CT.

SCAI and HRS release expert consensus on transcatheter left atrial appendage occlusion

One of the new recommendations is to conduct baseline imaging with TEE or cardiac CT.

Cardiologists, electrophysiologists ‘disappointed’ in final 2023 Medicare Physician Fee Schedule

The American College of Cardiology and Heart Rhythm Society issued a joint statement soon after CMS published its final rule for the 2023 Medicare Physician Fee Schedule. The groups warned that the final rule could threaten patient access to high-quality care. 

A FEOPS image of a Watchman LAA occluder device being checked for virtual sizing in an anatomical model of the patient's left atrial appendage. Dhanunjaya Lakkireddy, MD, explains the role and technology of LAA closure devices in managing AFib patients.

VIDEO: The value of left atrial appendage occlusion in AFib patients

Dhanunjaya Lakkireddy, MD, executive medical director for the Kansas City Heart Rhythm Institute at HCA Midwest Health, explains recent trials in left atrial appendage occlusion (LAAO) and how the therapy helps atrial fibrillation (AFib) patients. 

Brugada arrhythmogenic substrate that causes VT and sudden cardiac death. This study showed ablation of this substrate area could help prevent sudden cardiac arrest in these patients.

Epicardial ablation in Brugada syndrome reduces sudden cardiac death

A late-breaking study at Heart Rhythm 2022 found epicardial ablation in Brugada syndrome helped significantly reduce sudden cardiac arrest in these patients, increasing their survival.

Thumbnail

Same-day discharge for AFib ablation a success thanks to telehealth

The new analysis, presented during Heart Rhythm 2022, focused on patients treated at a high-volume facility during the COVID-19 pandemic.